Ajinomoto Bio-Pharma Services Competitors and Similar CompaniesClear all

Ajinomoto Bio-Pharma Services's competitors and similar companies include Oxford BioTherapeutics, CytomX Therapeutics, Lexicon Pharmaceuticals and Anika Therapeutics.

	Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO).	Oxford BioTherapeutics Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.	CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	Anika Therapeutics Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair.
Founding Date	Founding Date 1998	Founding Date 2004	Founding Date 2008	Founding Date 1995	Founding Date 1992
Type	Type Subsidiary	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development genetics healthtech medical diagnostics therapy	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development health & beauty
Locations	Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP	Locations Milton, GB HQ San Jose, US	Locations South San Francisco, US HQ	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Bedford, US HQ Padova, IT Padova, IT Franklin, US
Employees	Employees 7741% increase	Employees 482% decrease	Employees 15815% increase	Employees 20216% increase	Employees 15416% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 91.4 m	Valuation ($) 610.9 m	Valuation ($) 369.8 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) £2.1m (FY, 2018)	Revenue (est.) $101.2m (FY, 2023)	Revenue (est.) $1.2m (FY, 2023)	Revenue (est.) $166.7m (FY, 2023)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $85k (FY, 2023)	Cost of goods $63.6m (FY, 2023)
Net income	Net income N/A	Net income (£6.5m) (FY, 2018)	Net income ($569k) (FY, 2023)	Net income ($177.1m) (FY, 2023)	Net income ($82.7m) (FY, 2023)
Operating ⚠
Patents (Foreign)	Patents (Foreign) N/A	Patents (Foreign) N/A	Patents (Foreign) 4 (FY, 2016)	Patents (Foreign) N/A	Patents (Foreign) 151 (FY, 2016)
Patents (US)	Patents (US) N/A	Patents (US) N/A	Patents (US) 13 (FY, 2016)	Patents (US) N/A	Patents (US) 21 (FY, 2016)
Patents Pending	Patents Pending N/A	Patents Pending N/A	Patents Pending 144 (FY, 2016)	Patents Pending N/A	Patents Pending 14 (FY, 2016)
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products N/A
Pre-Clinical Phase Products	Pre-Clinical Phase Products N/A	Pre-Clinical Phase Products N/A	Pre-Clinical Phase Products 4 (FY, 2016)	Pre-Clinical Phase Products 1 (FY, 2016)	Pre-Clinical Phase Products N/A
Funding
Total funding raised	Total funding raised $ 3.5m	Total funding raised $ 21.6m	Total funding raised $ 132.4m	Total funding raised $ 244.7m	Total funding raised N/A